Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory trial of CEB-01 PLGA membrane in pancreatic cancer surgery
2024-512742-42-00Phase 2Suspended
- Sponsor
- Cebiotex
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of firtecan in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Cebiotex. Primary endpoints: Serious and non-serious adverse events and International Patient Safety Goals after pancreatic surgery. Started Jun 2024; status: suspended.
02
Drugs
firtecan
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-512742-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512742-42-00.